Decitabine

Decitabine is a type of medicine used to treat certain types of cancer, like leukemia. It works by helping the body's own cells fight the cancer. It's given as an injection.

Brand names:Dacogen
Medication

What people taking Decitabine report

Every report comes from a Lived member, sent anonymously.

Have you tried Decitabine for AML (Acute Myeloid Leukemia)?

NameHow it went

About Decitabine

What It's For

Decitabine is a cancer medicine used to treat myelodysplastic syndromes (MDS) in adults. MDS is a group of bone marrow disorders in which the marrow's stem cells fail to mature into healthy blood cells, leaving too few working red cells, white cells or platelets. That shortfall shows up as tiredness and shortness of breath from anemia, frequent infections, and easy bruising or bleeding. Decitabine is approved for intermediate- and higher-risk MDS, including chronic myelomonocytic leukemia (CMML), a related disorder, whether the MDS is newly found or has been treated before. It also treats newly diagnosed acute myeloid leukemia (AML), a fast-growing blood cancer, when combined with venetoclax (Venclexta), a targeted leukemia pill. This pairing is meant for adults 75 or older, or for people whose other health problems make intensive chemotherapy too risky. Decitabine comes in two forms. The intravenous form is now sold as a generic; it was originally marketed as Dacogen, a brand no longer sold in the US. Inqovi is a tablet that combines decitabine with a second ingredient, cedazuridine, so the medicine can be taken by mouth at home.

How It Works

Genes are switched on and off partly by small chemical tags, called methyl groups, attached to DNA. In MDS and AML, abnormal tagging can silence genes that normally tell blood cells to mature and stop dividing. Decitabine is taken up into the DNA of dividing cells and blocks the enzyme that adds these tags. As the tags are lost, some silenced genes may work again, and abnormal cells may mature or die. For this reason decitabine is often called a hypomethylating agent. Because it acts mainly on dividing cells, it also affects the healthy marrow that makes blood, which is why low blood counts are its main side effect. Taken alone by mouth, decitabine is broken down in the gut and liver by an enzyme called cytidine deaminase. The cedazuridine in Inqovi blocks that enzyme, so enough decitabine reaches the bloodstream.

Dosage & Administration

Decitabine is given in cycles: a few days of treatment followed by several weeks of rest so the bone marrow can recover. Intravenous decitabine is given by infusion into a vein at a clinic or infusion center, either as a one-hour infusion daily for five days every four weeks, or as a longer schedule of three-hour infusions every eight hours for three days, repeated every six weeks. The dose is based on body size, and anti-nausea medicine is often given beforehand. Inqovi is one tablet a day on days 1 through 5 of each 28-day cycle. It is taken on an empty stomach, at least two hours before or after eating, and swallowed whole without crushing, cutting or chewing. If you vomit after a dose, do not take another that day; take the next dose as scheduled. Inqovi and intravenous decitabine are not swapped for each other within a cycle. The care team checks blood counts before each cycle and may delay a cycle or lower the dose if counts have not recovered.

Side Effects

Low blood counts are the most important and most common effect. Most people develop low white cells, low platelets and anemia during treatment, and these drops can be serious or even fatal. Low white cells make infections such as pneumonia more likely and harder to fight. Low platelets raise the risk of bleeding. Transfusions, antibiotics or growth factors (injections that prompt the marrow to make more white blood cells) may be needed along the way. Nausea, constipation, diarrhea, tiredness and fever are also common, and some people get mouth sores, loss of appetite, joint or muscle aches, or rash. Call the care team right away for fever, chills, sore throat, cough or other signs of infection, or for unusual bleeding or bruising. With low white cells, an infection can become serious quickly.

Interactions & Warnings

Decitabine can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for six months after the last dose, and men with partners who could become pregnant should use it during treatment and for three months after. Breastfeeding is not recommended during treatment or for two weeks after the last dose. Intravenous decitabine has no well-known drug interactions, though formal interaction studies have not been done, so the care team should still know about all medicines and supplements. Inqovi is different: cedazuridine blocks cytidine deaminase, the enzyme that breaks down decitabine and some closely related cancer medicines, such as azacitidine, another drug used for MDS. Inqovi should not be combined with medicines broken down by that enzyme, because their levels and side effects could rise. The oncology team checks for this, so tell them about any other cancer treatment you receive. Intravenous decitabine has not been studied in people with existing kidney or liver problems, and Inqovi has not been studied in severe kidney disease or moderate to severe liver disease, so these are weighed before starting. The team also checks kidney and liver blood tests and may pause treatment if they worsen or if an infection is active.

What to Expect

Decitabine works slowly. Treatment usually continues for at least four cycles before judging whether it is helping, and some people respond only after more. In the main trial of intravenous decitabine for MDS, about 1 in 6 people had their blood counts and marrow return to normal or improve substantially, compared with none who received supportive care alone, and others had smaller improvements in their counts. Responses typically took about three months to appear. With Inqovi, about half of people who needed regular transfusions were able to go at least eight weeks without them. Blood counts often fall further during the first one or two cycles. This is expected and does not necessarily mean the disease is getting worse. Regular blood tests, and sometimes repeat bone marrow tests, track both side effects and response. If decitabine is working and tolerated, it is usually continued until it stops working or side effects become too much. Results vary widely. Some people go on to a stem cell transplant, while for others decitabine is the main long-term treatment.

Questions to Ask Your Doctor

  1. 1.What are the goals of decitabine for my type of MDS or AML, and how will we know if it is working?
  2. 2.Is intravenous decitabine or the Inqovi tablet a better fit for me, and how do the schedules compare?
  3. 3.How will we handle low blood counts, and when might I need transfusions, antibiotics or a delay in treatment?
  4. 4.What signs of infection or bleeding should make me call, and how do I reach the team after hours?
  5. 5.Am I a candidate for a stem cell transplant, and how does decitabine fit into that plan?

Last reviewed • Oct 2026

Educational content, not medical advice.